IL17A and neoplasm: Finally, consistent with a previous study in which IL-17A was shown to increase tumor immunogenicity and immune activation in the TDLNs by promoting DC recruitment23, we observed an increased CD8α+ DC population in the TDLNs of AdIL-17A-transduced tumors (Fig. 7).